CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,449,000 | -6.4% | 735,716 | -11.1% | 0.10% | +8.0% |
| Q2 2022 | $15,433,000 | -15.0% | 827,480 | 0.0% | 0.09% | -15.4% |
| Q1 2022 | $18,163,000 | -22.7% | 827,480 | 0.0% | 0.10% | -8.8% |
| Q4 2021 | $23,509,000 | +21.3% | 827,480 | -10.1% | 0.11% | +34.1% |
| Q3 2021 | $19,380,000 | +11.7% | 920,656 | 0.0% | 0.08% | +11.8% |
| Q2 2021 | $17,354,000 | +84.2% | 920,656 | +49.3% | 0.08% | +85.4% |
| Q1 2021 | $9,420,000 | +8.3% | 616,520 | 0.0% | 0.04% | +24.2% |
| Q4 2020 | $8,699,000 | +83.6% | 616,520 | +103.9% | 0.03% | +73.7% |
| Q3 2020 | $4,737,000 | -14.9% | 302,320 | -4.9% | 0.02% | -24.0% |
| Q2 2020 | $5,569,000 | +116.4% | 317,857 | +81.6% | 0.02% | +56.2% |
| Q1 2020 | $2,573,000 | -41.4% | 175,000 | 0.0% | 0.02% | -30.4% |
| Q4 2019 | $4,391,000 | +66.8% | 175,000 | 0.0% | 0.02% | +27.8% |
| Q3 2019 | $2,632,000 | -20.8% | 175,000 | +31.6% | 0.02% | -21.7% |
| Q2 2019 | $3,325,000 | +11.3% | 132,985 | +1.3% | 0.02% | +21.1% |
| Q1 2019 | $2,987,000 | -24.1% | 131,250 | 0.0% | 0.02% | -40.6% |
| Q4 2018 | $3,936,000 | +4.7% | 131,250 | 0.0% | 0.03% | +28.0% |
| Q3 2018 | $3,760,000 | – | 131,250 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |